Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

NCT03447314 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: GSK1795091
DRUG: GSK3174998
DRUG: GSK3359609
DRUG: Pembrolizumab

Sponsor

GlaxoSmithKline

Collaborators

[object Object]